Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    Online

    Nature-based Virtual Reality Intervention for Depression in Alzheimer’s Disease (VRN-AD)

    What is this Study about?

    This study looks at how an at-home nature-based virtual reality (VR) program may help people living with Alzheimer’s Disease manage behavioural and psychological symptoms of dementia (BPSD), such as depression. Caregivers and/or study partners will have the option of taking part in the study and providing feedback regarding the VR intervention. This project will explore how virtual reality can be used as a non-pharmacological approach to prolong aging in place for individuals with BPSD, as BPSD contributes to rates of institutionalization.

    Eligibility Criteria

    • Are 50 years or older
    • Have been diagnosed with mild to early-moderate Alzheimer's disease (including mixed dementia)
    • Are medically stable and able to take part safely
    • Experience mild to moderate depressive symptoms
    • Feel comfortable using basic technology, such as a tablet or headset
    • Have access to Wi-Fi and a smart device (such as a phone or tablet) for online sessions and study apps
    • Have someone available to be present during all study sessions

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)

    What is this Study about?

    The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

    Eligibility Criteria

    Male or female participants aged 50 years of age
    Has a history of previous clinical intracerebral hemorrhage.
    Has probable CAA.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

    What is this Study about?

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Must have a study partner
    Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    What is this Study about?

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Eligibility Criteria

    Male or female participants aged 55 years of age to 90.
    Must have a study partner
    History of agitation due to AD.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    UHN - TO Western - Dr. Tartaglia

    A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer

    What is this Study about?

    The purpose of this study is to:Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) and Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

    Eligibility Criteria

    Male or female participants aged 40 to 80 years of age
    Has mild cognitive impairment (MCI) or dementia due to AD

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Accelerated intermittent theta burst stimulation to enhance cognitive function and balance in dementia

    What is this Study about?

    McMaster University is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a noninvasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.

    Eligibility Criteria

    1.) Diagnosed with Dementia and/or memory loss by a clinician

    2.) Exhibit adequate oral communication skills and cognitive function

    3.) Walk or stand with or without personnel or assistive devices

    4.) Individuals must be greater than or equal to 50 years of age

    Recruitment End Date

    Find Out More
  • Observational Study
    In person & Online

    Assessing the Impact of Day programs on individuals living with Dementia and their family/friend Caregivers

    What is this Study about?

    This study explores how adult day programs affect the lives of people living with dementia and their caregivers across several Canadian regions. Over time, we gather information about health, well-being, daily experiences, and quality of life of people living with dementia who attend day program and their caregivers. We also aim to learn about day programs themselves, such as their activities, staffing, challenges, and successes. By combining surveys, interviews, and focus groups, our program of research aims to understand what makes day programs helpful, where challenges exist, and how day program can better support families, and people who use them.

    Eligibility Criteria

    You are eligible to participate if you:

    • Are an older adult living with dementia who attends or does not attend a day program

    • You are a family/friend caregiver of someone living with dementia who attends or does not attend a day program

    • Live in one of the participating regions (Ontario, Winnipeg MB, Calgary AB, or Interior BC)

    • Are able to take part in a conversation or complete surveys, with support if needed

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Validation of the Hearing and Functioning in Everyday Life Questionnaire for Cognitively impaired Older Adults

    What is this Study about?

    Hearing loss is the third most common chronic health condition among people 65 and older and increases the risk of social isolation, depression, communication difficulties and dementia. Dementia risk may be reduced through hearing rehabilitation, and it is critical to develop tools for identifying hearing loss and its impact on communication. The Hearing and Functioning in Everyday Life Questionnaire (HFEQ) is a measure to identify hearing loss and everyday life functioning, not yet been evaluated for people with combined hearing loss and cognitive impairment. To bridge this gap, the aim is to evaluate the HFEQ for this group. The study has a cross-sectional observational study design. Adults over 60 years, with hearing loss and with and without cognitive impairment will be recruited. Data collection will include a cognitive and hearing assessment, assessment of conversation effectiveness and efficiency, hearing and general health history and five questionnaires (HFEQ, the Life-Space questionnaire, the Social Functioning in Dementia scale, and the PROMIS anxiety and depression scales).

    Eligibility Criteria

    • Are 60 years or older

    • Have hearing loss

    • Experience cognitive complaints (subjective memory complaints, mild cognitive impairment, or dementia) or,

    • Experience no changes in cognitive function

    Recruitment End Date

    Find Out More
  • Observational Study
    In person & Online

    Using mobile technology to inform driving decision-making in dementia

    What is this Study about?

    This study will assess if an in-vehicle Driving Monitoring System can identify differences in driving behaviours between older adults who are cognitively healthy, those with mild cognitive impairment, and those with mild dementia. 

    Eligibility Criteria

    Participants must:

    • Be 65 years or older.

    • Be cognitively healthy or have mild cognitive impairment or mild dementia.

    • Have a valid General class driver’s license and still driving.

    • Be fluent in English.

    • Own an insured vehicle of 1998 or newer model year.

    • Drive to at least 2 different locations per week. 

    Recruitment End Date

    Find Out More